Education
About Us
Working with TipRanks
Follow Us
Biodesix (BDSX)
NASDAQ:BDSX
BDSX Stock Chart & Stats
$5.58
-$0.03(-2.01%)
At close: 4:00 PM EST
$5.58
-$0.03(-2.01%)
Day’s Range― - ―
52-Week Range$3.42 - $30.20
Previous CloseN/A
Volume171.18K
Average Volume (3M)107.55K
Market Cap
$44.39M
Enterprise Value$92.70M
Total Cash (Recent Filing)$16.70M
Total Debt (Recent Filing)$72.93M
Price to Earnings (P/E)―
Beta0.81
Next Earnings
Mar 17, 2026EPS Estimate
-0.94Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.16
Shares Outstanding7,955,685
10 Day Avg. Volume48,205
30 Day Avg. Volume107,552
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)9.50
Price to Sales (P/S)2.78
P/FCF Ratio-3.82
Enterprise Value/Market Cap2.09
Enterprise Value/Revenue1.16
Enterprise Value/Gross Profit1.45
Enterprise Value/Ebitda-3.50
Forecast
1Y Price Target
$30.00Price Target Upside437.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
EBITDA OutlookThe company reiterated its 2025 revenue guidance and expects to achieve positive adjusted EBITDA in the fourth quarter of 2025, driven by test volume growth.
Revenue GrowthBiodesix delivered a solid third-quarter print, with total revenue exceeding consensus by 3%.
Sales ExpansionBiodesix aims to expand its sales team significantly by year-end 2025, which is expected to help drive long-term revenue growth.
Bears Say
Balance Sheet ConcernsUntil questions over the profitability outlook and balance sheet concerns are answered, the stock remains at Market Perform.
Investor ConfidenceInvestor focus is likely to remain on the company’s path to AEBITDA positivity and cash flow breakeven.
Profitability ConcernsThere are still questions on cash runway and the team’s ability to reach AEBITDA profitability in the fourth quarter.
Biodesix News
BDSX FAQ
What was Biodesix’s price range in the past 12 months?
Biodesix lowest stock price was $3.42 and its highest was $30.20 in the past 12 months.
What is Biodesix’s market cap?
Biodesix’s market cap is $44.39M.
When is Biodesix’s upcoming earnings report date?
Biodesix’s upcoming earnings report date is Mar 17, 2026 which is in 65 days.
How were Biodesix’s earnings last quarter?
Biodesix released its earnings results on Nov 03, 2025. The company reported -$1.16 earnings per share for the quarter, beating the consensus estimate of -$1.49 by $0.33.
Is Biodesix overvalued?
According to Wall Street analysts Biodesix’s price is currently Undervalued.
Does Biodesix pay dividends?
Biodesix does not currently pay dividends.
What is Biodesix’s EPS estimate?
Biodesix’s EPS estimate is -0.94.
How many shares outstanding does Biodesix have?
Biodesix has 7,955,685 shares outstanding.
What happened to Biodesix’s price movement after its last earnings report?
Biodesix reported an EPS of -$1.16 in its last earnings report, beating expectations of -$1.49. Following the earnings report the stock price went up 19.874%.
Which hedge fund is a major shareholder of Biodesix?
Currently, no hedge funds are holding shares in BDSX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biodesix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.00 (437.63% Upside)
$30.00 (437.63% Upside)
Hedge Fund Trend
Increased
By 8.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 8.5%
Last 30 Days ▼ 8.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-79.44%
12-Months-Change
Fundamentals
Return on Equity
-302.55%
Trailing 12-Months
Asset Growth
-24.26%
Trailing 12-Months
Company Description
Biodesix
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also offers GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a 72-hour blood-based NGS test. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.
BDSX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Biodesix showed strong revenue growth, improved gross margins, and significant progress in lung diagnostics and development services. However, unresolved issues with Medicare Advantage payments and an existing net loss highlight ongoing challenges. Overall, the achievements and positive trends in growth and operational improvements suggest a positive outlook.View all BDSX earnings summariesBDSX Stock 12 Month Forecast
Average Price Target
$30.00
▲(437.63% Upside)